Pharmafile Logo

Glaucoma in perspective

- PMLiVE

Alnylam gets EU nod for Onpattro amid pricing backlash

However the drug’s price could be lowered in the EU due to direct competition

AstraZeneca AZ

AstraZeneca’s Lupus treatment misses mark in trial

Anifrolumab failed to show statistically significant reduction in disease activity

- PMLiVE

Social care crisis looms as demand to double by 2035

England unprepared after years of delaying hard decisions

- PMLiVE

Pfizer abandons antibody for Duchenne

Latest to fail in myostatin inhibitor class

- PMLiVE

Powerful digital content management for the life sciences

Anthill Agency, a leading life sciences digital agency, has unveiled Anthill Activator™, which enables Veeva users to more efficiently manage their digital resources. Activator makes it easy to create and...

Anthill Agency

- PMLiVE

UK pharma Code of Practice to change with digital times

Changes proposed on the Code’s 60th anniversary

- PMLiVE

Roche highlights Hemlibra data as key FDA date approaches

Expanded use would see revenues take off

- PMLiVE

ICER says Alnylam’s Onpattro should cost 90%-95% less

Even after discounts the medication exceeds the cost-effectiveness threshold

Pitch Perfect

What makes a perfect pitch? This week’s Thirsty Thursday – hosted by Louise Verrall, a managing director at Lucid Partners – was all about just that.Louise started her session with an involved...

Lucid Group Communications Limited

Roche Basel Switzerland

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Deal is latest in series of big pharma investments in cancer immunotherapies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links